Elevance Health, Inc. $ELV Shares Sold by Vulcan Value Partners LLC

Vulcan Value Partners LLC decreased its position in shares of Elevance Health, Inc. (NYSE:ELV) by 7.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 386,214 shares of the company’s stock after selling 32,981 shares during the period. Elevance Health accounts for about 2.4% of Vulcan Value Partners LLC’s holdings, making the stock its 13th largest position. Vulcan Value Partners LLC’s holdings in Elevance Health were worth $135,424,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ELV. Vanguard Group Inc. raised its position in Elevance Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after purchasing an additional 141,747 shares in the last quarter. Wellington Management Group LLP raised its position in Elevance Health by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock valued at $2,139,473,000 after purchasing an additional 303,099 shares in the last quarter. Artisan Partners Limited Partnership raised its position in Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after purchasing an additional 901,626 shares in the last quarter. First Eagle Investment Management LLC raised its position in Elevance Health by 0.6% in the 4th quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock valued at $1,410,219,000 after purchasing an additional 24,271 shares in the last quarter. Finally, Invesco Ltd. raised its position in Elevance Health by 22.9% in the 3rd quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock valued at $839,300,000 after purchasing an additional 484,303 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Bank of America raised Elevance Health from a “neutral” rating to a “buy” rating and increased their price target for the company from $405.00 to $435.00 in a research report on Wednesday, April 29th. Guggenheim increased their price target on Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. Barclays increased their price target on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, UBS Group increased their price target on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $403.11.

Elevance Health Trading Up 0.8%

NYSE:ELV opened at $391.00 on Thursday. The stock’s 50 day moving average price is $339.83 and its 200 day moving average price is $337.98. The company has a market capitalization of $84.91 billion, a PE ratio of 16.63, a P/E/G ratio of 2.20 and a beta of 0.66. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $408.00.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts anticipate that Elevance Health, Inc. will post 26.91 EPS for the current year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.